Author Response to Letter to Editor regarding “Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?”-Reference-Cited by-同舟云学术

Author Response to Letter to Editor regarding “Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?”

Published:2024-08-16 Issue: Volume: Page:
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Campisi Giuseppina,Mauceri Rodolfo,Coppini Martina,Bedogni Alberto,Bertoldo Francesco,Fusco Vittorio

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00198-024-07192-4.pdf

Reference8 articles.

1. Cordova LA, Gonzalez-Quintanilla D, Heymann D (2024) Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care? Osteoporos Int. https://doi.org/10.1007/s00198-024-07173-7

2. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg 80(5):920–943. https://doi.org/10.1016/j.joms.2022.02.008

3. Bedogni A et al (2024) Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). Oral Dis. https://doi.org/10.1111/odi.14887

4. Coleman R et al (2020) Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol 31(12):1650–1663. https://doi.org/10.1016/j.annonc.2020.07.019

5. Mauceri R, Coppini M, Campisi G (2022) Onset of MRONJ in breast cancer patients after switching from low to high dose of bone modifying agents due to bone metastases development: a single center retrospective cohort study. Oral 2(4):274–285. https://doi.org/10.3390/oral2040026